Standard BioTools Inc. LAB
0.74
0.00
0.00%
as of 25 Sep
- Market cap
- $291.7M
- P/E
- 3.4×
Follow LAB
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 17.61% | 15.40% | (16.72%) | (28.85%) |
+8 more TTM periods Free account |
|
| 14.34% | 12.83% | (12.69%) | (21.00%) | ||
ROIC |
(93.89%) | (56.34%) | (29.07%) | (29.24%) | |
Return on Tangible Assets |
17.86% | 15.76% | (20.51%) | (33.29%) | |
Average Days of Receivables |
67.94 | 176.19 | 57.45 | 79.14 | |
Free Cash Flow per Share |
(0.21) | (0.24) | (0.22) | (0.26) | |
Free Cash Flow |
(82.58) | (94.48) | (82.65) | (98.42) | |
Capital Expenditures |
(2.28) | (3.82) | (8.30) | (11.21) | |
Piotroski F-Score |
5.00 | 5.00 | 3.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(7.90%) | (8.92%) | (12.14%) | (14.66%) | |
Accounts Receivable Turnover |
5.57 | 2.24 | 6.06 | 2.56 | |
Accounts Payable Turnover |
4.96 | 4.39 | 8.18 | 3.77 | |
Inventory Turnover |
2.03 | 1.43 | 2.10 | 0.97 | |
Average Days of Payables |
83.25 | 67.26 | 46.12 | 73.06 | |
Days of Inventory on Hand |
149.03 | 156.19 | 170.45 | 280.54 | |
Tax Rate |
(0.41) | (0.43) | (0.39) | (0.02) | |
Research and Development Expense of Revenue |
21.77% | 26.28% | 30.45% | 26.73% | |
Selling, General and Administrative Expense of Revenue |
102.75% | 114.36% | 128.75% | 146.27% | |
Share Based Compensation of Revenue |
32.02% | 34.12% | 34.70% | 50.20% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(0.95) | (1.16) | 0.99 | 0.68 | |
Depreciation/Fixed assets |
0.17 | 0.34 | 0.43 | 0.50 | |
Capex/Depreciation |
(0.88) | (0.66) | (1.00) | (1.09) | |
Revenue per Share |
0.22 | 0.22 | 0.22 | 0.16 | |
Operating CF per Share |
(0.21) | (0.23) | (0.19) | (0.23) | |
Capex per Share |
(0.01) | (0.01) | (0.02) | (0.03) | |
Capex to Sales |
0.03 | 0.04 | 0.10 | 0.18 | |
Net Profit Margin |
100.37% | 90.67% | (87.77%) | (205.44%) |
Columns are period end dates